Compare BridgeBio Pharma Inc (BBIO) vs Solaredge Technologies Inc (SEDG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Solaredge Technologies Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Solaredge Technologies Inc trades at $33.5 (market cap $1.98B). The key difference: BridgeBio Pharma Inc is far larger — about 8.4× Solaredge Technologies Inc's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Solaredge Technologies Inc nearer its low. Which is the better fit depends on your goals.
| BBIO | SEDG | |
|---|---|---|
Market Cap | $16.61B | $1.98B |
Sector | Health | Technology |
52-Week High | $90.17 | $78.51 |
52-Week Low | $47.29 | $25.10 |
Enterprise Value | $18.16B | $1.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
SolarEdge Technologies (SEDG) trades at $31.76, down 2.79% amid weak Q3 2026 revenue guidance overshadowing a Q2 earnings beat. The stock exhibits a bearish technical trend with key support at $30 and resistance at $34. Fundamentally, the company reported a net loss of $405.45 million in 2025, though revenue grew to $1.18 billion, with profitability metrics like ROE at -58.42% reflecting ongoing challenges in the residential solar market.
The outlook remains cautious due to persistent losses and competitive pressures, but analyst consensus suggests a potential upside to $35.15. Key risks include soft U.S. demand and execution hurdles, while institutional sentiment is mixed with 20.83% buy ratings. Investors should weigh cost-control progress against macroeconomic headwinds in the solar sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Solaredge Technologies Inc
SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers. Additionally, the company has nonsolar products targeting energy storage and e-mobility.
Read more on SEDG →
